---
document_datetime: 2023-09-21 18:23:34
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/zavesca-epar-procedural-steps-taken-authorisation_en.pdf
document_name: zavesca-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.4025863
conversion_datetime: 2025-12-21 17:50:36.153389
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant Oxford GlycoSciences (UK) Ltd submitted on 29 June 2001 an application for Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) through the centralised procedure for Zavesca, which was designated as an orphan medicinal product EU/3/00/006 on 18 October 2000.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

Rapporteur: Dr Per Nilsson Co-Rapporteur: Prof Rolf Bass

## Licensing status:

The product was not licensed in any country at the time of submission of the application.

## 2. Steps taken for the assessment of the product

- The procedure started on 17 July 2001.
- The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on  26 September  2001.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP members on 27 September 2001.
- During the meeting on 13 - 15 November 2001 the CPMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 15 November 2001.
- The  company  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on  23 January 2002.
- The summary report of the inspection  carried  out  at  the  manufacturing  site  on  11  December 2001 was issued on 12 February 2002.
- The Rapporteur circulated the response Assessment Report on the company's responses to the List of Questions to all CPMP members on 25 February 2002.
- During the meeting on 19 - 21 March 2002 the CPMP adopted a list of outstanding issues to be addressed by the applicant in writing. The list of outstanding issues was sent to the applicant on 21 March 2002.
- The applicant provided written information on these outstanding issues to all CPMP members on  26  April  2002  and  15  May  2002.  The  Rapporteur/Co-Rapporteurs'  joint  review  on  the responses to the list of outstanding issues was circulated to all CPMP members on 14 May 2002 and an amended version on 22 May 2002.
- Concurrent with the CPMP meeting on 25 - 27 June 2002, an ad-hoc clinical expert meeting took place on 24 June 2002 and a report was adopted by the CPMP on 27 June 2002.
- During  the  CPMP  meeting  on  25  -  27  June  2002,  outstanding  issues  were  addressed  by  the applicant on 25 June 2002 during an oral hearing before the CPMP.
- The  applicant  provided  written  information  to  all  CPMP  Members  on  15  July  2002.  The Rapporteur/Co-Rapporteurs' joint review of the written information was circulated to all CPMP members on 16 July 2002.
- During the meeting on 23 - 25 July 2002 the CPMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation to Zavesca on 25 July 2002.
- The CPMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 20 November 2002.